Construction of recombinant adenovirus vector containing a modified gene that codes for human hypoxia-inducible factor-1α without oxygen-dependent degradation domain

Plasmid

Volumn 63, Issue 1, 2010, Pages 20-26

  Wei, Liang ^a   Lu, Jun ^a   Feng, Li ^a   Li, Shengfu ^a   Shan, Juan ^a   Li, Youping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chronic graft dysfunction; HIF 1 ; HO 1; Human cardiomyocytes; Ischemia reperfusion injury; Recombinant adenovirus

Indexed keywords

ADENOVIRUS VECTOR; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENE SEQUENCE; GRAFT DYSFUNCTION; HEART GRAFT; HEART MUSCLE CELL; HUMAN; HUMAN CELL; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; BASE SEQUENCE; DNA, RECOMBINANT; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MOLECULAR SEQUENCE DATA; MYOCYTES, CARDIAC; OXYGEN; PLASMIDS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RNA, MESSENGER; SEQUENCE DELETION; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA;

EID: 72649088597     PISSN: 0147619X     EISSN: 10959890     Source Type: Journal    
DOI: 10.1016/j.plasmid.2009.09.002     Document Type: Article

References (23)

1. Bishopric N.H., Andreka P., Slepak T., and Webster K.A. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr. Opin. Pharmacol. 1 (2001) 141-150
2. Christ M., Lusky M., Stoeckel F., Dreyer D., Dieterlé A., Michou A.I., Pavirani A., and Mehtali M. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol. Lett. 57 (1997) 19-25
3. Dawn B., and Bolli R. HO-1 induction by HIF-1: a new mechanism for delayed cardioprotection?. Am. J. Physiol. Heart Circ. Physiol. 289 2 (2005) 542-548
4. Elson D.A., Thurston G., Huang L.E., Ginzinger D.G., McDonald D.M., Johnson R.S., and Arbeit J.M. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev. 15 (2001) 2520-2532
5. Fujishiro J., Kawana H., Inoue S., Shimizu H., Yoshino H., Hakamata Y., Kaneko T., Murakami T., Hashizume K., and Kobayashi E. Efficiency of adenovirus-mediated gene transduction in heart grafts in rats. Transplant. Proc. 37 1 (2005) 67-69
6. Greenlund J.S., Deckwerth T.L., and Johnson E.M. Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron 14 (1995) 303-315
7. Hellwig-Bürgel T., Stiehl D.P., Wagner A.E., Metzen E., and Jelkmann W. Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J. Interferon Cytokine Res. 25 (2005) 297-310
8. Hirota K., and Semenza G.L. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem. Biophys. Res. Commun. 338 (2005) 610-616
9. Holweg C.T., Balk A.H., Snaathorst J., van den Engel S., Niesters H.G., Maat A.W., Zondervan P.E., Weimar W., and Baan C.C. Intragraft heme oxygenase-1 and coronary artery disease after heart transplantation. Transplant. Immunol. 13 (2004) 265-272
10. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95 (1998) 7987-7992
11. Huang Y., Hickey R.P., Yeh J.L., Liu D., Dadak A., Young L.H., Johnson R.S., and Giordano F.J. Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J. 18 (2004) 1138-1140
12. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
13. Jassem W., and Heaton N.D. The role of mitochondria in ischemia/reperfusion injury in organ transplantation. Kidney Int. 66 (2004) 514-517
14. Kultz D. Molecular and evolutionary basis of the cellular stress response. Annu. Rev. Physiol. 67 (2005) 225-257
15. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
16. Otterbein L.E., and Choi A.M. Heme oxygenase: colors of defense against cellular stress. Am. J. Physiol. Lung Cell Mol. Physiol. 279 (2000) 1029-1037
17. Racusen L.C., Halloran P.F., and Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am. J. Transplant. 4 (2004) 1562-1566
18. Ryter S.W., Otterbein L.E., Morse D., and Choi A.M. Heme oxygenase/carbon monoxide signaling pathways: regulation and functional significance. Mol. Cell. Biochem. 234-235 (2002) 249-263
19. Semenza G.L., and Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12 (1992) 5447-5454
20. Tsui T.Y., Wu X., Lau C.K., Ho D.W., Xu T., Siu Y.T., and Fan S.T. Prevention of chronic deterioration of heart allograft by recombinant adeno-associated virus-mediated heme oxygenase-1 gene transfer. Circulation 107 (2003) 2623-2629
21. Tullius S.G., and Tilney N.L. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 59 (1995) 313-318
22. Tullius S.G., Reutzel-Selke A., Egermann F., Nieminen-Kelha M., Jonas S., Bechstein W.O., Volk H.D., and Neuhaus P. Contribution of prolonged ischemia and donor age to chronic renal allograft dysfunction. J. Am. Soc. Nephrol. 11 (2000) 1317-1324
23. 2 tension. Proc. Natl. Acad. Sci. USA 92 (1995) 5510-5514